Both mimic the activity of endogenous GLP-1, regulating blood glucose levels by increasing insulin secretion, inhibiting glucagon secretion, delaying gastric motility, and increasing feelings of satiety
Its peptides are sold for research use only, and BPC-157 though removed from the FDAs interim category-2 compounding list on procedural grounds in April 2026 was flagged over significant safety concerns and remains unapproved and under regulatory review
"Our new analyses provide assurance that the medication, when taken by individuals who are free of significant mental health concerns, does not increase the risk of depression, suicidal thoughts, or suicidal behavior," said lead author Professor Thomas A
Approximately one-third of infertility issues are caused by male reproductive issues
Injection medications typically produce faster absorption and more predictable blood levels than oral formulations, potentially explaining their lower starting costs at PlexusDx
Regulators mandated these labels at launch because long-term data was insufficient to rule out risks